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The Extent of the Problem
Stroke, about 80% of which is ischae-
mic caused by occlusion of an intracere-
bral artery and 20% caused by intracere-
bral bleeding, is the second most common
cause of death and disability globally.
WHO statistics indicate that stroke and
other cerebrovascular diseases kill approx-
imately 5.7 million people each year. In
the United States alone it is estimated that
the 780,000 symptomatic strokes detected
each year may be accompanied by a
further 11 million asymptomatic strokes
[1]. The need to reduce this burden by
better use of existing therapies and iden-
tification of new ones is pressing.
Stroke Mechanisms and
Pathophysiology: Heterogeneity Is
the Key
A unique feature of stroke that creates
opportunities for new therapies is the
heterogeneity of its mechanisms. These
range from large artery to artery embo-
lism, cardiac embolism to in situ small
vessel disease and even arterial dissection.
Intracerebral haemorrhage may be caused
by hypertensive small vessel disease, am-
yloid angiopathy, or rupture of saccular
aneurysms. Risk factors such as atrial
fibrillation, hypertension, smoking, diabe-
tes, and disordered lipid metabolism
contribute to underlying atherosclerosis
or embolus formation [2]. The sequence
of events, termed the ischaemic cascade,
that follows an ischaemic stroke has also
been established [3]. Here, neurons ex-
posed to extreme reductions in blood flow
(the ‘‘ischaemic core’’) lose their mem-
brane potential, undergo irreversible struc-
tural damage, and die. In surrounding
regions (the ‘‘ischaemic penumbra’’) the
reduction in blood flow is sufficient to
compromise neuronal function but not
immediately cause neuronal death. A
balance between energy supply and con-
sumption exits and tissue survival is
determined by the depth and duration of
ischaemia [3,4]. An understanding of this
process has led to the concept of reperfu-
sion and neuroprotective therapies.
Twenty Years of Rapid but
‘‘Inherited’’ Advances
Interestingly,manytherapeuticadvances
in stroke have come from research in other
disciplines. For example, blood pressure
lowering agents such as the ACE inhibitors,
developed originally to reduce the risk of
vascular injury and myocardial infarction
were found to reduce stroke incidence
[5,6]. Similarly for the statins, designed to
reduce LDL-cholesterol were found to
protect against stroke [7]. Thrombolysis
and anti-platelet therapies developed from
ischaemic heart disease management [8],
and hemicraniectomy to relieve pressure in
some cases of ischaemic stroke was used in
head trauma [9]. Even some stroke care
unit management practices have come
from approaches developed in cardiology,
oncology, burns, and transplant medicine
[10]. We have ‘‘inherited’’ the majority of
four categories of acute and five of
secondary prevention interventions with
level 1 evidence of benefit in stroke since
1978 in this way (see Table 1). As this
approach has been successful in the past,
abandoning it now would be unwise: we
suggest a continued monitoring of other
disciplines, while also pursuing novel
stroke-specific research. We will address
the likely wins from existing classes of
intervention and then speculate from where
the next therapeutic classes may emerge.
The Next Generation of
Treatments: New Twists on
Existing Therapies
Primary and Secondary Prevention
The greatest early gains are likely to
come from enhancing existing strategies.
Declines in stroke incidence and mortality
in developed countries are most likely due
to better risk factor control [11]. However,
not all of the reduction in stroke mortality
may have come from better blood pressure
control. Benefits may have accrued from
the recently recognised anti-inflammatory
effects of ACE inhibitors and statins [12],
and an inflammatory genesis of athero-
sclerosis may create opportunities for new
therapeutic targets. Better recognition of
atrial fibrillation (AF), the risk factor that is
often overlooked in spite of its high age-
specific attributable risk [13], is necessary
and may lead to new opportunities.
Prevention of stroke in AF with new
classes of drugs such as the thrombin
inhibitors is a reality [14]. With the
growing impact of metabolic syndrome
[15], incretin-based therapies, which help
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emia [16], combined with better lifestyle
management may also be useful in the
future. Anti-platelet agents have been a
mainstay of secondary stroke prevention
(Table 1). However, a ceiling may have
been reached of about 20% relative risk
reduction, and further anti-platelet effects
may cause unacceptable bleeding [17].
Compounds with actions ‘‘beyond the
platelet’’ need to be identified, such as
thromboxane receptor antagonists.
Can imaging and other biomarkers
assist in the search for new therapies?
Although currently little evidence indicates
that this would be cost effective, screening
to detect asymptomatic aneurysms, varia-
tions in Circle of Willis anatomy [18] and
arterial collateralization [19] may ulti-
mately prove useful. For example, patients
with reduced capacity to redistribute
cerebral blood flow and thus maintain
perfusion above ischemic thresholds are
likely to be susceptible to larger strokes.
Reports that variation in expression of
molecules such as thrombin activatable
fibrinolysis inhibitor (TAFI) [20] and
plasminogen activator inhibitor-1 (PAI-1)
[21] might define risk in specific stroke
subsets needs evaluation in the general
population. Bioinformatics may help assess
panels of protein or mRNA biomarkers to
assess stroke risk. Systems controlling
clotting and fibrinolysis and regulating
inflammation or oxidative stress may be
particularly informative.
Acute Stroke
Novel approaches to thromboly-
sis. Recanalisation and restoration of
blood flow by thrombolysis with tissue
plasminogen activator (tPA) benefits only a
small proportion of stroke patients [22].
The narrow 3-hour time window and the
risk of bleeding limit its use [23]. The time
window has now been extended to
4.5 hours, and penumbral imaging with
MR or CT may extend this further
[24,25]. The development of biomarker
assays for stroke duration or individual risk
of bleeding may increase the proportion of
eligible patients. Biomarker assays may
also be used to improve the toxicity profile
of thrombolytic agents and help develop
ways to make thrombolytics safer, for
example by using the platelet-derived
growth factor receptor, alpha (PDGFR-a)
antagonist imatinib to reduce tPA-induced
bleeding [26]. Another possibility is TAFI,
with a genotype associated with stroke risk
[27], circulating activity that modifies
outcome after thrombolytic therapy [28]
and the capacity to make clots resistant to
heparins [29]. With the potential to reduce
time to artery opening by up to 90 minutes
[30], TAFI inhibitors might be effective
and safe profibrinolytic agents for use with
existing thrombolytic therapies [31].
Mechanical clot removal/disrup-
tion. The use of mechanical devices to
remove clots after the acute stroke event is
a logical approach but it is highly labour-
and capital-intensive. Early recanalisa-
tion success was demonstrated with the
MERCI Retriever embolectomy device
[32] and has been followed by a number
of others, most recently the Penumbra
device [33]. While it remains to be proved
Table 1. Acute interventions and secondary prevention strategies of proven benefit based on level I evidence.
Category Evidence Level Intervention
Initial or Important Study, Year
[Reference] RRR ARR NNT1
Acute stroke Proven Stroke unit Langhorne et al., 1993 [10] 6.5% 3.8% 26
Thrombolysis (tPA) NINDS, 1995[58] 9.8% 5.5% 18
Aspirin IST, 1997[59] 2.6% 1?2% 83
Decompression surgery for IS Vahedi et al., 2007 [9] 48.8% 23% 4
a
Under evaluation Recombinant factor 7 for ICH Mayer et al., 2005[60] — — —
Surgery for ICH Mendelow et al., 2005[61] — — —
Extending time window for thrombolysis DIAS, 2005[62] — — —
Sonothrombolysis Alexandrov et al., 2004[63] — — —
Thrombectomy MERCI, 2005[32] — — —
Blood pressure lowering ENOS, 2007[64] — — —
Neuroprotection SAINT, 2006[65] — — —
Secondary
prevention
Proven Aspirin Canadian Co-op Study Group[66] 13.0% 1.0% 100
Aspirin plus dipyridamole Diener, 1996[67] 15.0% 1.9% 53
Clopidogrel CAPRIE, 1996[68] 10.0% 1.6% 62
Anticoagulants EAFT, 1993[69] 66.0% 8.0% 11
Carotid endarterectomy NASCET, 1991[70]; ECST, 1991[71] 44.0% 3.8% 26
Blood pressure lowering PROGRESS, 2001[72] 28.0% 4.0% 97
b
Cholesterol lowering SPARCL, 2006[73] 16.0% 2.2% 220
b
Under evaluation Angioplasty Yadav et al, 2004[74] — — —
Thrombin inhibitors RELY, 2009 [14] — — —
The number needed to treat (NNT1) to prevent one stroke patient dying or becoming dependent (acute stroke), or to prevent one fatal or non-fatal stroke (secondary
prevention), per year, are given. All figures are approximate and derived from previous analyses, the Cochrane database, or individual trials if these are the only data
available. Modified from Donnan et al. [2],
aNNT for survival with mRS#3.
bCalculations based on mean follow-up of 3.9 y in PROGRESS (NNT3.9=25) and median 4.9 y in SPARCL (NNT4.9=45).
ARR, absolute risk reduction; ICH, intracerebral haemorrhage; IS, ischaemic stroke; NNT, number needed to treat; RRR, relative risk reduction.
doi:10.1371/journal.pmed.1000224.t001
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shift from thrombolysis to more direct
catheter-based intervention in acute myo-
cardial ischemia management, a similar
pattern for acute stroke is likely. Oppor-
tunities exist to develop improved clot-
retrieval devices and, more importantly,
health care system changes to allow
deployment effectively in a timely manner.
Neuroprotection. Despite disappoint-
ments in the area of neuroprotection, the
rhetoric ‘‘neuroprotection is dead’’ seems
premature. Systematic reviews and meta-
analyses have revealed deficiencies in
experimental designs. Failure to consider
bias [34] and comorbidities common in
human stroke [35] all lead to over-
optimistic interpretations of preclinical
animal testing. A more rational approach
is needed in the sequence of animal to
human studies. The heterogeneity of stroke
supports the breadth of preclinical evalua-
tion recommended by the Stroke Therapy
Academic Industry Roundtable (STAIR)
[36], while the fundamentals of good
science demand careful bias avoidance
[34]. In addition it would seem desirable
to have evidence that new drugs reach their
hypothesised targets and elicit at least a
surrogate response once there. Hypother-
mia does tick all the appropriate preclinical
boxes [37] and has been found to be
effective in protecting against the neur-
ological sequelae of cardiac arrest [38]; a
large-scale Phase III trial instrokeisneeded
in spite of logistical difficulties. Also, com-
pounds that directly depress body tem-
perature should perhaps be considered. For
example, improgan, a member of a new
class of nonopioid analgesics, can reduce
core temperature in rodents by 1uC within
10 minutes [39], and hydrogen sulphide
can rapidly induce a suspended animation-
like state [40]. Drugs that alter the
thermoregulatory set-point and make
hypothermia more tolerable by reducing
shivering are already being considered
[41]. We should also entertain alternative
mechanisms of action of hypothermia
such as control of oedema and local
compression.
Timing of treatment following stroke is
critical. It may be that neuroprotection is
of value only if reperfusion ultimately
occurs. In other disciplines, graft ischae-
mia times for renal, cardiac, and lung
transplantation due to developments in
effective cold storage and preservative
fluids are impressive. Hence ‘‘freezing’’
the penumbra with neuroprotectants may
be a realistic goal while waiting for
reperfusion. An example is with normo-
baric oxygen, which increases penumbral
oxygen partial pressure and reduces in-
farct volume in animals [42]. Prolongation
of penumbral survival has been inferred in
Phase II MR-based studies and pilots of
therapy performed in humans [43].
Where May the Next New Class
of Therapies Come From?
Although a number of avenues of
research may bring rewards in terms of
completely new classes of intervention for
the prevention and treatment of stroke, we
believe two areas are most likely to
generate completely new classes of thera-
peutic targets.
Stimulation of Plasticity
One of the most important advances in
neuroscience has been the recognition of
activity-dependent plasticity. Synapses, the
base units of connectivity, form and
disappear depending upon activity and
experience, and axons and dendrites can
reach out to and withdraw from new
targets [44]. Although it had become
established that astrocytes and microglia
respond rapidly to injury, the realisation
that new neurons and supporting oligo-
dendroglia could be generated from pools
of neural stem cells and progenitors was a
paradigm shift in neurology [45,46].
These processes offer new and exciting
therapeutic opportunities. At the simplest
level, we can use observations of benefit
after enriching the environment or in-
creasing motor activity to improve tradi-
tional rehabilitation strategies [47]. Effec-
tive delivery of growth-promoting factors,
including the nerve growth factor and glial
cell line-derived neurotrophic factor fam-
ilies of proteins, to enhance plasticity and
regeneration may also prove effective.
Alternatively, mobilization and activation
of endogenous neurogenesis/plasticity
with drugs such as granulocyte colony-
stimulating factor (G-CSF) may be attrac-
tive [48]. Although stem cell implants into
the brain may currently deliver only a
supportive or plastic environment that aids
recovery, these cells can mature and
integrate into the host neural circuitry
[49]. Given that repopulation of connec-
tive tissue scaffolds by stem cells can
reconstitute a beating animal heart [50],
the same may ultimately be possible for
regions of damaged brain.
Importantly, evidence is emerging that
neural recovery and immune function are
intimately linked [51]. Neural outputs
seem to regulate bone marrow and spleen
activity, while cytokines and related mol-
ecules act both locally and systemically to
facilitate neuroimmune communication.
While this interaction provides consider-
able scope for clinical intervention, for
example by using G-CSF to mobilise
neural stem cells [48] or manipulating
microglial or macrophage mediated axo-
nal plasticity [52], it is a double-edged
sword. Many of the candidate molecular
targets directly influence both acute injury
development and later neurovascular re-
modelling [53]. Our approaches need to
be sophisticated enough to deal with these
critical temporal issues.
Unravelling the Genetic Code to the
Heterogeneity of Stroke
There is about a 40% gap in the
population attributable risk for stroke
when all known risk factors are considered
[54]. Much of the gap may consist of
genetic contributions to risk in some form.
Fortunately, there have been enormous
advances in the genetics of stroke. Initial
linkage analysis studies identified, rare
conditions such as CADASIL (cerebral
autosomal dominant arteriopathy with
subcortical infarcts and leucoencephalop-
athy) due to mutations in the NOTCH3
gene [55], which is involved in cell
signalling and fate during embryonic
development. Subsequently, a candidate
gene approach using case-control designs
produced a large number of potential gene
polymorphisms, many of which could not
be replicated and were probably the
product of underpowered studies. The
emergence of the concept of polygenic
contributions to the stroke syndrome, gene
chip technology and genome-wide associ-
ation studies (GWASs) has revolutionized
the area. Large international cooperative
studies with sample sizes in the thousands
have enabled investigators to produce
reliable data. For example, by genotyping
more than 310,000 single-nucleotide poly-
morphisms (SNPs) in more than 1,700
intracranial aneurysms and 7,400 controls,
SNPs on Chromosomes 2q, 8q, and 9p
were associated with aneurysmal presence.
The biological implications come from an
understanding of the function of these
genes as our research effort explores their
biology. Chromosomes 8q and 9p both
have genes that are associated with
progenitor cells and expressed in blood
vessels. The main candidate gene on 8q is
SOX17, which is required for endothelial
formation and maintenance [56]. The
implications for the development of gene-
based or other therapies are obvious.
Similarly, investigators of the International
Stroke Genetics Consortium found an
association between SNPs in the Chromo-
some 9p21.3 region and large-artery
stroke [57]. GWASs are still in their
infancy and are dependent on careful
PLoS Medicine | www.plosmedicine.org 3 March 2010 | Volume 7 | Issue 3 | e1000224phenotyping and large sample sizes. How-
ever, the likelihood that completely novel
therapeutic classes emerge from these
studies is extremely high.
Summary
Remarkable progress has occurred over
the last two decades in stroke interven-
tions. Many have been developed on the
basis of their efficacy in other disorders.
This ‘‘inheritance’’ approach should con-
tinue, but two areas where completely
novel therapeutic targets might emerge are
the stimulation of neuroplasticity and
unraveling the genetic code of stroke
heterogeneity (Table 2). For the former,
the next steps are to identify small-
molecule, nontoxic compounds that most
effectively enhance plasticity in animal
models, and then subject them to clinical
trial in humans. For the latter, more and
larger-scale cooperative GWASs in care-
fully phenotyped stroke populations are
required to better understand the poly-
genic nature of cerebrovascular disease.
Then, the physiological relevance of
genetic abnormalities can be determined
in in vitro and in vivo systems before
candidate compounds are developed.
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